<DOC>
	<DOCNO>NCT01697579</DOCNO>
	<brief_summary>The purpose study determine appropriate dose regimen fosaprepitant , administer ondansetron ( without dexamethasone ) , prevention CINV child birth &lt; 17 year age . Fosaprepitant prodrug aprepitant . All participant complete randomize Cycle 1 may elect receive open-label fosaprepitant optional Cycles 2-6 .</brief_summary>
	<brief_title>Study Pharmacokinetics , Pharmacodynamics , Safety Tolerability Fosaprepitant Prevention Chemotherapy-Induced Nausea Vomiting ( CINV ) Children ( MK-0517-029 )</brief_title>
	<detailed_description>Under Amendment 01 , 0517-029 enrol participant follow age cohort : 2- &lt; 6 , 6- &lt; 12 12-17 year old . The study randomize , partially-blinded , parallel group assignment . Participants randomize one three fosaprepitant dos control group . ( Amendment 02 Amendment 03 country-specific amendment Brazil require per local regulation change study design . ) Under Amendment 04 , 12-17 year old cohort close since cohort fully enrol . An additional fosaprepitant dose add participant allocate one treatment group . Amendment 04 open-label enrol participant follow age cohort : 0- &lt; 2 , 2- &lt; 6 6- &lt; 12 year old .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Is 0 month ( least 37 week gestation ) &lt; 18 year age Scheduled receive chemotherapeutic agent ( ) associate moderate , high , high risk emetogenicity 5 consecutive day document malignancy , chemotherapy regimen previously tolerate due vomit Expected receive ondansetron part antiemetic regimen ( Cycle 1 ) ; Expected receive 5HT3 antagonist part antiemetic regimen ( Cycles 26 ) If female begin menstruating , must negative pregnancy test prior study participation agree remain abstinent use barrier form contraception Predicted life expectancy ≥3 month Preexisting functioning central venous catheter Weight ≥3rd percentile age gender ( ≥3.0 kg ) Vomited 24 hour prior study drug administration ( Cycle 1 ) Current user illicit drug ( include marijuana ) current evidence alcohol abuse Scheduled receive stem cell rescue therapy conjunction study related course ( ) emetogenic chemotherapy Received receive radiation therapy abdomen pelvis week prior study drug administration and/or course study Pregnant breast feed Allergic fosaprepitant , aprepitant , ondansetron , 5HT3 antagonist Has symptomatic central nervous system ( CNS ) tumor cause nausea and/or vomiting Has active infection , congestive heart failure , slow heart rate , uncontrolled disease cancer Mentally incapacitate significant emotional psychiatric disorder Known history QT prolongation take medication know lead QT prolongation Taking exclude medication Participated previous study aprepitant fosaprepitant , take investigational drug within 4 week prior study participation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>